AIDS Therapy

Biopharma inks agreement with Guangdong Medicine Group Corp.

Published in Immunotherapy Weekly, October 1st, 2003

Hemispherx Biopharma, Inc., (HEB) announced that it has signed an agreement with Guangdong Medicine Group Corp. to organize clinical trials, marketing, sales, and distribution for both of its lead compounds, Alferon N and Ampligen, in the People's Republic of China.

The agreement stipulates that the Guangdong Medicine Group Corp. (GMC) will conduct clinical trials with Alferon N Injection, a natural source, multispecies, alpha interferon product, for the treatment of HCV, and with Ampligen, a double-stranded RNA experimental compound acting potentially as an immunomodulator and antiviral, for the treatment of HIV. All costs related to these trials are covered by...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Immunotherapy Weekly

Source: Immunotherapy Weekly (2003-10-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry